NCI Center for Cancer Research shared a post on LinkedIn about a paper by
“In 70% of head and neck squamous cell carcinoma (HNSCC) cases, researchers have observed an excess of the gene MAP3K13, which produces a protein called LZK. A team at CCR developed a proteolysis-targeting chimera (PROTAC) that induces LZK degradation, resulting in reduced HNSCC cell survival. This study provides the basis for developing more LZK-targeted therapeutics, particularly PROTACS, to effectively treat HNSCC.
Image: Chemical structure of GNE-3511, an inhibitor of LZK.”
Title: Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors
Authors: Amy L Funk, Meghri Katerji, Marwa Afifi, Katherine Nyswaner, Carolyn C Woodroofe, Zoe C Edwards, Eric Lindberg, Knickole L Bergman, Nancy R Gough, Maxine R Rubin, Kamila Karpińska, Eleanor W Trotter, Sweta Dash, Amy L Ries, Amy James, Christina M Robinson, Simone Difilippantonio, Baktiar O Karim, Ting-Chia Chang, Li Chen, Xin Xu, James H Doroshow, Ivan Ahel, Anna A Marusiak, Rolf E Swenson, Steven D Cappell, John Brognard
You can read the Full Article in Science Signaling.
More posts featuring NCI Center for Cancer Research.
